BioNTech SE's (BNTX) stock soared 5.01% in the pre-market trading session on Thursday, February 13, 2025. The rally was fueled by reports denying the involvement of the Wuhan Institute of Virology in the creation or leakage of the COVID-19 virus that led to the global pandemic.
China's Foreign Ministry spokesperson, Guo Jiakun, reiterated that the Wuhan Institute of Virology played no role in the design, production, or release of the SARS-CoV-2 virus that caused the COVID-19 pandemic. This statement comes after reports emerged about the U.S. Agency for International Development (USAID) funding gain-of-function studies at the institute, which could have triggered the worldwide outbreak.
The denial from Chinese authorities has bolstered confidence in BioNTech, one of the leading developers of COVID-19 vaccines. BioNTech's partnership with Pfizer produced the Comirnaty vaccine, which has been widely used globally in the fight against the pandemic. The positive news has alleviated concerns about potential liabilities related to the vaccine's development and distribution, driving the stock's surge.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。